Sean S Bell

US Patent:

7537923, May 26, 2009

Filed:

Apr 22, 2008

Appl. No.:

12/107736

Inventors:

Emil D. Kakkis - Novato CA, US
Paul A. Fitzpatrick - Albany CA, US
Daniel J. Wendt - Walnut Creek CA, US
Sean M. Bell - San Rafael CA, US
Augustus O. Okhamafe - Concord CA, US

Assignee:

BioMarin Pharmaceutical Inc. - Novato CA

International Classification:

C12N 9/88
A61K 38/00

US Classification:

435232, 530345

Abstract:

The present invention is directed to phenylalanine ammonia-lyase (PAL) variants produced by prokaryotes, wherein such prokaryotic PAL variant has a greater phenylalanine-converting activity and/or a reduced immunogenicity as compared to a wild-type PAL. The invention provides compositions of prokaryotic PAL and biologically active fragments, mutants, variants or analogs thereof, as well as methods for the production, purification, and use of such compositions for therapeutic purposes, including the treatment of cancer.

US Patent:

7790433, Sep 7, 2010

Filed:

Apr 9, 2009

Appl. No.:

12/421557

Inventors:

Emil D. Kakkis - Novato CA, US
Paul A. Fitzpatrick - Albany CA, US
Daniel J. Wendt - Walnut Creek CA, US
Sean M. Bell - San Rafael CA, US
Augustus O. Okhamafe - Concord CA, US

Assignee:

BioMarin Pharmaceutical Inc. - Novato CA

International Classification:

C12N 9/88
A61K 38/00

US Classification:

435232, 530345

Abstract:

The present invention is directed to phenylalanine ammonia-lyase (PAL) variants produced by prokaryotes, wherein such prokaryotic PAL variant has a greater phenylalanine-converting activity and/or a reduced immunogenicity as compared to a wild-type PAL. The invention provides compositions of prokaryotic PAL and biologically active fragments, mutants, variants or analogs thereof, as well as methods for the production, purification, and use of such compositions for therapeutic purposes, including the treatment of cancer.

US Patent:

8377884, Feb 19, 2013

Filed:

Nov 21, 2008

Appl. No.:

12/744079

Inventors:

Daniel J. Wendt - Walnut Creek CA, US
Sean Bell - San Rafael CA, US
Dong Wei - San Francisco CA, US
Joshua R. Bliesath - Escondido CA, US
Emil D. Kakkis - Novato CA, US

Assignee:

Biomarin Pharmaceutical Inc. - Novato CA

International Classification:

A61K 38/00
A61K 38/16
A61K 38/10

US Classification:

514 167, 514 213, 514 214, 530324, 530300

Abstract:

The present invention provides variants of C-type natriuretic peptide (CNP) comprising one or more deletions; additions of and/or substitutions with natural amino acids, unnatural amino acids and/or peptidomimetics (including peptide bond isosteres); amino acid extensions; and/or other chemical moieties such as, e. g. , poly(ethylene glycol) and hydrophobic acids. The CNP variants are useful as therapeutic agents for the treatment of diseases responsive to CNP, including but not limited to bone-related disorders such as, e. g. , skeletal dysplasias and achondroplasia, and vascular smooth muscle disorders such as, e. g. , restenosis and arteriosclerosis.

US Patent:

20100278802, Nov 4, 2010

Filed:

Jul 9, 2010

Appl. No.:

12/833911

Inventors:

Emil D. KAKKIS - Novato CA, US
Paul A. Fitzpatrick - Albany CA, US
Daniel J. Wendt - Walnut Creek CA, US
Sean M. Bell - San Rafael CA, US
Augustus O. Okhamafe - Concord CA, US

Assignee:

BioMarin Pharmaceutical Inc. - Novato CA

International Classification:

A61K 38/51
A61P 35/00

US Classification:

424 945

Abstract:

The present invention is directed to phenylalanine ammonia-lyase (PAL) variants produced by prokaryotes, wherein such prokaryotic PAL variant has a greater phenylalanine-converting activity and/or a reduced immunogenicity as compared to a wild-type PAL. The invention provides compositions of prokaryotic PAL and biologically active fragments, mutants, variants or analogs thereof, as well as methods for the production, purification, and use of such compositions for therapeutic purposes, including the treatment of cancer.

US Patent:

20130039898, Feb 14, 2013

Filed:

Feb 3, 2011

Appl. No.:

13/576625

Inventors:

Augustus O. Okhamafe - Concord CA, US
Sean M. Bell - Novato CA, US
G. Nick Zecherle - Novato CA, US
Kris Antonsen - San Rafael CA, US
Yanhong Zhang - San Rafael CA, US
Kieu Ly Tran - San Francisco CA, US
Paul A. Fitzpatrick - Berkeley CA, US
Emil D. Kakkis - Novato CA, US
Michel Claude Vellard - San Rafael CA, US
Daniel J. Wendt - Walnut Creek CA, US
Mubarack Muthalif - Novato CA, US

Assignee:

BIOMARIN PHARMACEUTICAL INC. - NOVATO CA

International Classification:

A61K 38/51
A61P 3/00
A61P 7/00
C12N 9/88

US Classification:

424 945, 435232

Abstract:

Provided herein are phenylalanine ammonia-lyase (PAL) variants produced by prokaryotes, wherein such prokaryotic PAL variant has a greater phenylalanine-converting activity and/or a reduced immunogenicity as compared to a wild-type PAL. Further provided are compositions of prokaryotic PAL and biologically active fragments, mutants, variants or analogs thereof, as well as methods for the production, purification, formulation, and use of such compositions for industrial and therapeutic purposes, e.g., treating hyperphenylalaninemia, including phenylketonuria, and other disorders, including cancer.

US Patent:

20190345475, Nov 14, 2019

Filed:

Jan 11, 2019

Appl. No.:

16/246300

Inventors:

- Novato CA, US
Sean M. Bell - Novato CA, US
G. Nick Zecherle - Novato CA, US
Kris Antonsen - San Rafael CA, US
Yanhong Zhang - San Rafael CA, US
Kieu Ly Tran - San Francisco CA, US
Paul A. Fitzpatrick - Berkeley CA, US
Emil D. Kakkis - San Rafael CA, US
Michel Claude Vellard - San Rafael CA, US
Daniel J. Wendt - Walnut Creek CA, US
Mubarack Muthalif - Novato CA, US

Assignee:

BIOMARIN PHARMACEUTICAL INC. - Novato CA

International Classification:

C12N 9/88
A61K 47/60
A61K 9/00
C07K 1/14
A61K 38/51

Abstract:

Provided herein are phenylalanine ammonia-lyase (PAL) variants produced by prokaryotes, wherein such prokaryotic PAL variant has a greater phenylalanine-converting activity and/or a reduced immunogenicity as compared to a wild-type PAL. Further provided are compositions of prokaryotic PAL and biologically active fragments, mutants, variants or analogs thereof, as well as methods for the production, purification, formulation, and use of such compositions for industrial and therapeutic purposes, e.g., treating hyperphenylalaninemia, including phenylketonuria, and other disorders, including cancer.

US Patent:

20160362675, Dec 15, 2016

Filed:

Apr 15, 2016

Appl. No.:

15/130694

Inventors:

- Novato CA, US
Sean M. Bell - Novato CA, US
G. Nick Zecherle - Novato CA, US
Kris Antonsen - San Rafael CA, US
Yanhong Zhang - San Rafael CA, US
Kieu Ly Tran - San Francisco CA, US
Paul A. Fitzpatrick - Berkeley CA, US
Emil D. Kakkis - San Rafael CA, US
Michel Claude Vellard - San Rafael CA, US
Daniel J. Wendt - Walnut Creek CA, US
Mubarack Muthalif - Novato CA, US

International Classification:

C12N 9/88
A61K 47/48
A61K 38/51

Abstract:

Provided herein are phenylalanine ammonia-lyase (PAL) variants produced by prokaryotes, wherein such prokaryotic PAL variant has a greater phenylalanine-converting activity and/or a reduced immunogenicity as compared to a wild-type PAL. Further provided are compositions of prokaryotic PAL and biologically active fragments, mutants, variants or analogs thereof, as well as methods for the production, purification, formulation, and use of such compositions for industrial and therapeutic purposes, e.g., treating hyperphenylalaninemia, including phenylketonuria, and other disorders, including cancer.